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Objective: To determine the combined in-vitro effects of azithromycin plus the fluoroquinolone ofloxacin or 
lomefloxacin against gram-positive and gram-negative bacteria. 
Methods: Fractional inhibitory (FIC) and fractional bactericidal concentration indices of azithrornycin and the 
fluoroquinolone were determined using a microtiter-checkerboard method. Clinical isolates of Staphylococcus aureus, 
Streptococcus pneumoniae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa. 
Pseudomonas cepacia, Haemophilus influenzae, Xanthomonas maltophilia and Acinetobacter calcoaceticus were 
studied. Fourteen strains of S. aureus were also studied in time-kill curves with azithromycin (4 mg/L), lomefloxacin (6 
mg/L) and the two in combination. 
Results: No synergism or antagonism was found in inhibitory assays. However, bactericidal assays revealed 
antagonism with some strains of S. aureus, S. pneumoniae, X. maltophilia, A. calcoaceticus, I? aeruginosa, F! cepacia, 
K. pneumoniae and E. coli. Kill-curve results with 14 strains of S. aureus showed no antagonism with four strains of 
methicillin-resistant S. aureus (MRSA), and antagonism with one strain of MRSA and seven methicillin-susceptible S. 
aureus (MSSA). 
Conclusions: In-vitro exposure to combinations of azithromycin and a fluoroquinolone does not produce a synergistic 
effect. Antagonism was found in bactericidal assays against some gram-negative bacteria and MSSA; caution is 
therefore recommended in the use of macrolides and quinolones against these organisms. 
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Azithromycin is a new azalide antibiotic with activity 
against a broad range of intra- and extracellular 
bacteria, and with approved indications, among others, 
in the treatment of respiratory tract infections and 
genital infections caused by Chlamydia tvuchomatis. 
Ofloxacin and lomefloxacin are fluoroquinolones with 
indications in the treatment of many infections of the 
respiratory and urinary tracts as well as some genital 
infections. As the combined use of azithroniycin and a 
fluoroquinolone may occur in the treatment of some 
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respiratory infections, urethritis, cervicitis or other 
infections, it is important to examine the potential for 
any synergism or antagonisni that might arise if azalides 
are used with quinolones. 
The objective of this study was to determine 
the combined in-vitro effects of azithrornycin plus 
ofloxacin or lomefloxacin against representative 
bacteria using two methods. First, a broad range 
of gram-positive and gram-negative bacteria was 
evaluated using the checkerboard titration method. 
Second, selected bacteria were studied using the time- 
kill method. 
MATERIALS AND METHODS 
Antimicrobial agents 
Azithromycin was provided by Pfizer Research 
Laboratories, Inc. (Groton, CT). Ofloxacin was 
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provided by Ortho Pharmaceuticals (Raritan, NJ) and 
lomefloxacin by Searle Pharmaceuticals (Chicago, IL). 
All compounds were prepared for testing according to 
instructional guidelines of the manufacturer. 
Bacterial strains 
All strains used in these studies were clinical isolates 
obtained from the microbiology laboratories of Brown 
University affiliated hospitals (Memorial Hospital of 
Rhode Island, The Miriam Hospital, Rhode Island 
Hospital and Roger Williams Medical Center) or 
reference strains obtained from the American Type 
Culture Center (ATCC). One strain of methicillin- 
resistant Staphylococcus aureus (MRSA) was obtained 
from Miles Pharmaceuticals, West Haven, CT. 
Microtiter-checkerboard titration 
Minimum inhibitory concentrations (MIC) were 
determined for each organism according to National 
Committee for Clinical Laboratory Standards (NCCLS) 
guidelines, using standard two-fold antibiotic micro- 
dilutions in broth [I]. Checkerboard-titration tests were 
performed following the guidelines detailed by 
Eliopoulos and Moellering [2]. Log-phase bacteria 
were diluted to a final inoculum approximating 
1 X lo5 to 1 X lo6 CFU/mL. Mueller-Hinton broth and 
Mueller-Hinton agar supplemented with calcium and 
magnesium were used for testing MIC and minimum 
bactericidal concentration (MBC) for most bacteria. 
Streptococcus pneumoniae was studied in brain-heart 
infusion broth and on Mueller-Hinton agar with 5% 
sheep blood. Neisseria gonorrhoeae was studied in brain- 
heart infusion broth and on chocolate Mueller-Hinton 
agar [incubation time of 20 h at 37°C with 3 to 5% 
carbon dioxide (CO2)]. Studies with Haemophilus 
intuenzae followed the current NCCLS guidelines [I]. 
Initial cultures were prepared in unsupplemented 
Mueller-Hinton broth incubated at 35°C in 3 to 5% 
COz for 16 to 18 h. All subsequent bacterial and 
antibiotic dilutions were performed with haemophilus 
test medium (BBL, Becton Dickinson), and microtiter 
plates were incubated at 35" C for 20 h. MBCs were 
studied on chocolate Mueller-Hinton agar plates 
incubated at 35" C in 3 to 5% COz for 20 h. 
Fractional inhibitory concentration (FIC) indices 
were calculated as the sum of the FIC of drug A plus 
the FIC of drug B, where the FIC was calculated as the 
MIC of the drug in combination divided by the MIC 
of the drug acting alone. Similar calculations were made 
for the fractional bactericidal concentration (FBC) 
index. An FIC or FBC index I 0.5 reflected a 
synergistic interaction whereas an FIC or FBC index 
>2.0 reflected an antagonistic interaction. All ranges 
between these values were considered to be either 
additive or indifferent. All experiments were performed 
in duplicate and the average of two values was used in 
all calculations. 
Strains that exhibited checkerboard results that 
might have potential clinical implications were further 
studied using the time-kill method. Additional strains 
of S. aureus were obtained for this expanded testing. 
lime-kill studies 
Time-kill curve studies were performed using no 
antibiotic, azithromycin alone (4 pg/mL), lomefloxacin 
alone (6 pg/mL) and the two drugs in combination. 
Log-phase bacteria were added to achieve a final 
inoculum of 1 X lo6 CFU/mL. Samples were taken at 
0 h and following incubation at 37" C at 2, 4, 6, 8, 10, 
12 and 24 h. Samples were subcultured on agar and 
quantitative colony counts determined [3]. 
RESULTS 
Checkerboard titration 
The results of checkerboard titration with azithromycin 
plus ofloxacin are summarized in Table 1. In all of 
the inhibitory assays, FIC indices ranged between 1 
and 2, implying an indifferent effect of the combi- 
nation. With a few strains of Klebsiella pneumoniae and 
S. aureus, replicate analyses yielded FBC indices > 2, 
indicating antagonism. (One strain of S. pneumoniae 
and an ATCC strain of H. inzuenzae yielded FBC 
indices of 2.5.) 
Similarly, azithromycin plus lomefloxacin resulted 
in FIC indices I 2 with the exception of one strain each 
of Acinetobacter cakoaceticus, Xanthomonas maltophilia, and 
Pseudomonas cepacia (Table 2). One strain each of 
Pseudomonas aeruginosa, I? cepacia, K. pneumoniae, A .  
calcoaceticus, Escherichia coli and S. pneumoniae, and all 
three tested strains of X .  maltophilia showed consistent 
evidence of antagonism in bactericidal assays (FBC 
indices ranging from 3 to 17). No antagonism was 
demonstrated with either fluoroquinolone in combin- 
ation with azithromycin among any of the strains of 
Neisseria gonorrhoeae tested. Fourteen strains of MRSA 
and methicillin-susceptible S. aureus (MSSA) were also 
studied with lomefloxacin and azithromycin (Table 3). 
FIC indices ranged from 2 to 3, but six MSSA and 1 
MRSA showed evidence of bactericidal antagonism 
with FBC indices 2 4.5. Thirteen of these staphylo- 
cocci strains were tested in time-kill assays. 
lime-kill studies 
Time-kill curves were constructed using azithromycin 
at 4 mg/L and lomefloxacin at 6 mg/L, and a total of 
one strain of K. pneumoniae (MIC/MBC: azithromycin 
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Table 1 Minimum inhibitory (MIC), and fractional inhibitory (FIC) and bactericidal (FBC) 
concentrations of ofloxacin and azithromycin alone and in combination 
Ofloxacin MIC Azithromycin 
FBC index Organism (P&L) MIC (pg/mL) FIC index 
Neisseria gcinorrhoeae 
ATCC 49226 0.01 0.12 2 2 
N. ~(inorrhoeae 
1331 
N. gomrrliorae 
1365 
Esrlierichia rofi 
ATCC 25922 
E. coli 
107 
E.  roli 
D-295 
0.007 0.03 1.75 1.5 
0.01 0.06 2 1 
0.06 
0.25 
0.25 
Klebsieffa pneumoniae 
ATCC 3883 0.25 
K. pneumotiiae 
24 1 
K. pneumorrioe 
106 
8 
16 
64 
16 
1.5 
2 
2 
1 0.875 
2 64 2 3.5 
4 32 2 1 
IJseudomonns aerugiuosa 
ATCC 27853 16 512 1.5 1 
l? aerngitiosa 
1681 
P aevuginoso 
14 
64 256 2 2 
4 128 1.5 1 
Sfaphylocorcias aurrns 
ATCC 25923 0.5 1.1 2 7.75 
S. aureus 
ATCC 29213 1.5 2 2 10 
S. aurais 
MKSA MP 1200 1 2 512 
Sfrep tococcus pneumouiae 
ATCC 6305 2 
S. ptienniowiae 
4050 2 
S. pueumoniac 
71 2 
Haemophilus ir$uenzae 
ATCC 49247 1 
2 2 
0.03 1.75 2 
0.06 1.25 2 
0.03 1.75 2.5 
0.06 2 2.5 
H .  iq¶nenzae 
155 
H. influenme 
292-1 
0.5 0.03 2 1 
1 0.03 1.75 2.5 
ATCC = American Type Culture Center 
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Table 2 Minimum inhibitory (MIC), and fractional inhibitory (FIC) and bactericidal (FBC) 
concentrations of lomefloxacin and azithromycin alone and in combination 
~ ~~ 
Ofloxacin MIC Azithromycm 
Organism (PdmL) MIC (pg/mL) FIC index FBC index 
Neisseria gonorrhoeae 
ATCC 49226 
h! gonorrhoeae 
1331 
N. pnorrhueae 
1365 
N. gonorrhoeae 
1403 
N. gonorrhoeae 
01 
Escherichia coli 
ATCC 25922 
E. coli 
107 
E. coli 
D-295 
Klebsiella pneumoniae 
ATCC 13883 
K. pneumoniae 
24 1 
K. pneumoniae 
106 
Pseudomonas aeruginosa 
ATCC 27853 
J? aeruzinosa 
1681 
I? aeruginosa 
14 
Pseudomonas cepacia 
ATCC 49127 
I? cepacia 
88-17 
I? cepacia 
88-22 
I? cepacia 
9 1-28 
Xarithomonas maltophilia 
00 
X .  maltophilia 
02 
X .  maltophilia 
03 
Acinetobacter calcoaceticus 
00 
A .  calcoaceticus 
01 
A.  calcoaceticus 
2016 
Streptococcus pneumoniae 
ATCC 6305 
S. pneumoniae 
4050 
S. pneumoniae 
71 
0.015 
0.015 
0.015 
0.015 
0.008 
0.125 
0.25 
0.125 
0.25 
2 
4 
16 
64 
4 
4 
4 
4 
16 
2 
2 
2 
8 
0.5 
16 
4 
8 
x 
0 06 
0.03 
0.03 
0.03 
0.03 
8 
8 
8 
8 
64 
32 
128 
256 
128 
128 
64 
256 
128 
128 
16 
16 
32 
2 
32 
0.03 
0.125 
n.o6 
2 
1 
1 
2 
1.5 
1.5 
1.5 
2 
2 
2 
2 
2.5 
2 
2 
3 
2 
1.5 
2 
2.5 
3 
3 
2 
6 
1 
2.5 
1.5 
1 
1.75 
2 
2 
2 
2 
1 
4 
0.75 
2 
12 
3 
1.5 
2.75 
1.5 
3 
2 
2 
1.5 
4.5 
3 
3 
2 
5 
2 
3 
2.5 
2 
ATCC = American Type Culture Center. 
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Table 3 Mininium inhibitory (MIC), and fractional inhibitory (FIC) concentrations of lomefloxacin 
and azithroniycin alone and in combination against 14 strains of methicillin- susceptible (MSSA) and 
niethicillin-resistant (MRSA) Staphylocoacrs ni~reus 
Ofloxacin MIC Azithroniycin 
Organism (Wl11 L) MI(: (pg/mL) FIC index FRC index 
MRSA" 
MP1200 0.5 2 512 3 3 
MRSA 
J 1 2 512 2 2 
MRSA 
1281 1 256 2 8.5 
MKSA 
1707 1 2 512 2 '. 3 
MRSA 
409 03 2 512 3 3 
MRSA 
64 1 0.5 2 512 3 2 
MRSA 
8495 256 2 512 2 1.2.5 
MSSA 
ATCC 25923 0. .5 0.5 2 13 
MSSA 
ATCC 29213 
MSSA 
401B 
MSSA 
1351R 
MSSA 
3221 
MSSA 
44H 
MSSA 
47u 
7 - 2 2 16 
1 2 2 5 
1 2 3 5 
1 2 512 2 - 3
1 1 2 8.5 
1 1 2 4 5  
'Not te\ted in kill curve. 
ATCC: = American Type Culture Center 
64/128 nig/L; lornefloxacin 2 i2  nigiL) ,  six strains of 
MKSA (generously supplied by John Boyce), five 
strains o f  MSSA (also supplied by John Boyce) and two 
ATCC strains of MSSA. All of the MRSA strains had 
MICs and MBCs o f  azithroniycin 2 256 mg/L. Six of 
seven MRSA strains had lomefloxacin MICs 5 1 mg/L 
with similar MBCs. MRSA strain 8495 had a 
loniefloxacin MIC and MBC 2 256 mg/L. Six of the 
seven MSSA strains had azithroniycin MICs 5 2 nig/L 
with MBCk ranging from 8 to > 32 mg/L. MSSA strain 
3221 was highly resistant to azithromycin (MIC and 
MBC 2 512 nig/L). The two ATCC S. uweus strains 
were susceptible to loniefloxacin (MIC 1 nig/L; MBC 
S 2 mg/L) and moderately susceptible to azithroniycin 
(MIC I 2 nig/L; MBC 5 16 nig/L). 
Three distinct patterns were obtained in the kill- 
curve studies. Figure 1 (A) reveals no killing with 
azithromycin alone, and good killing with lomefloxacin 
alone and the two drugs in combination, This pattern 
was found with K. pneiimowiar 241 (FIC index = 2; 
FBC index = 12), and with four MRSA strains sensitive 
to loniefloxacin, but resistant to azithroniycin, with 
FIC and FBC indices ranging from 2 to 3 (strains J, 
1707, 499 and 641). Figure 1(B) showed no effect of 
lomefloxacin alone, azithroniycin alone or the two in 
combination. This pattern was seen only with MILSA 
8495, which was resistant to both loniefloxacin and 
azithromycin (MICs 2 256 mg/L; FIC index = 2, FBC 
index = I .25). Figure I (C)  shows good killing with 
lomefloxacin alone, approximately 12 11 of inhibition 
with azithroniycin alone, and an antagonistic effect of 
the conibination (compared with loniefloxacin alone) 
with approximately two logs less killing than with 
lornefloxacin alone. This pattern was found with all 
seven MSSA strains and MRSA 1281 (FIC indices 
ranged from 2 to 3; FBC indices all but 1 2 4.5). 
188 C l i n i c a l  Microbio logy and I n f e c t i o n ,  Vo lume 1 Number  3 
DISCUSSION 
The results of these studies suggest that combination 
therapy with quinolones and azithromycin are unlikely 
to provide synergistic killing against any particular 
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Figure 1 Sample kill-curve patterns found with: (A) 
MRSA strains susceptible to lomefloxacin, but resistant to 
azithromycin, with FIC and FBC indices of 2 to 3 (strains J, 
1707, 499 and 641), and Klebsiellapneumoniae 241; (B) 
MRSA strain 8495, resistant to lomefloxacin and 
azithromycin (FIC and FBC indices = 2 and 1.25); and (C)  
MSSA strains ATCC 25923, ATCC 29213, 401B, 1351B, 
3221, 44B, 47B and MRSA 1281. 
bacterial species, and that some strains of S. aureus may 
not be well killed by this combination. Most of the 
examples of  antagonistic interaction o f  these two 
antibiotics were seen with staphylococcal strains, 
especially those that were susceptible to methicillin 
(and lomefloxacin and azithromycin!). Checkerboard 
antagonism was also found for some strains o f  X .  
maltopkilia, l? cepacia and A. cakoaceticus, organisms that 
are not likely to be treated with this combination. 
The results of FBC index determinations corre- 
lated reasonably well with kill-curve experiments - 
FBC indices 2 4 predicted an antagonistic response 
in the time-kill curves, and those between 2 and 3 
showed an indifferent effect with the lomefloxacin plus 
azithromycin combination. One possible exception 
was found with MSSA strain 3221, where minimal 
antagonism was found with the combination compared 
with the most active drug acting alone during the first 
8 h of killing, but with only a one-log difference after 
12 h (FBC index = 2). Antagonism was found more 
frequently among the MSSA strains which, with one 
exception (strain 3221), were susceptible to both 
azithromycin and the fluoroquinolone. These data 
suggest that azithromycin and fluoroquinolones should 
not be combined in the treatment of serious staphy- 
lococcal infections, especially if high-level azalide 
resistance is present. 
No significant antagonism and no synergism was 
found with azithromycin and the two fluoroquinolones 
tested with other bacteria, notably, N. gonorrkoeae, S. 
pneumoniae and H .  infuenzae. This suggests that the 
potential use o f  these drugs in combination for 
urethritis or common bacterial respiratory tract infec- 
tions is unlikely to result in antibiotic antagonism. 
There are relatively little data in the literature 
regarding macrolide plus quinolone combinations. A 
recent review by Neu [4] suggested that neither 
synergism nor antagonism was reported frequently with 
fluoroquinolones and other antibiotics whereas Haller 
[5] has reported some antagonism with ciprofloxacin 
and erythromycin against MSSA and some enterococci. 
Some Mycobacterium species may show favorable inter- 
actions with macrolides and quinolones (among other 
antibiotics). 
Clinicians are most likely to combine the new 
azalide azithromycin with a fluoroquinolone in the 
treatment of urethritis of unknown etiology where the 
possibility of gonococcal and chlamydia1 coinfection is 
reasonable. Similarly, it is conceivable that these two 
classes of antibiotics could be used by some physicians 
in the treatment of respiratory tract infections (although 
this practice is not recommended). Therefore, it is 
encouraging to note that no antagonism was seen in 
vitro when azithromycin was combined with either 
Ruble :  I n - v i t r o  i n t e r a c t i o n  of a z i t h r o m y c i n  a n d  f l u o r o q u i n o l o n e s  189  
lomefloxacin or ofloxdcin against the gonococci or 
respiratory tract pathogens tested in the present study. 
However, because of the consistent demonstration 
of in-vitro bactericidal antagonism with S. aureus 
(especially MSSA), caution is recommended against the 
use of macrolides and fluoroquinolones in combination 
to treat infections caused by these organisms. Experi- 
ence with experimental animal models or clinical 
infections is needed to fully interpret these results. 
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